Slides
Page 1
© 2026 Haemonetics Corporation JP Morgan 44th Annual Healthcare Conference January 13, 2026
Page 2
2 Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “forecasts,” “foresees,” “potential” and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for operations of Haemonetics Corporation (“Haemonetics” or the “Company”), including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed or to be filed with the U.S. Securities Exchange Commission (the “SEC”) under the headings “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” and in the Company’s other periodic filings with the SEC. The Company does not undertake to update these forward-looking statements. Non-GAAP Financial Measures This presentation contains non-GAAP financial measures as defined under applicable SEC rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. To the extent available without unreasonable effort, we have provided reconciliations of these non-GAAP measures to their most comparable GAAP measure in the appendix to this presentation, which is available on our website at www.haemonetics.com. With the exception of fiscal 2026 revenue guidance, the Company does not provide a reconciliation of forward-looking non-GAAP measures because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts. When used in this release, organic revenue growth excludes the impact of currency fluctuation, acquisitions and divestitures. Organic ex-CSL revenue growth further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. Adjusted operating income, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, asset impairments and write downs, amortization of fair value inventory step-up, costs related to compliance with the European Union Medical Device Regulation and In Vitro Diagnostic Regulation, acquisition, integration and divestiture related costs, net gains on the repurchase of convertible notes, gains on sales of property, plant and equipment, certain tax settlements, unusual or infrequent and material litigation-related charges, and remeasurement of contingent consideration liability. Adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment. Important Information © 2026 Haemonetics Corporation2
Page 3
Haemonetics at a Glance © 2026 Haemonetics Corporation FY’25 REVENUE HAE NYSE ticker 3000+ employees ~$4.0B Market Cap1 Blood Management Technologies Interventional Technologies $1.36B 3 1) Market capitalization as of January 12, 2026. ~74% United States ~13% Europe ~7% Asia ~5% Japan 1% Rest of World 22.7% 18.8% 3
Page 4
4 FY’23 – FY’26 Transformational Growth GOALS DIVERSIFICATION • Business Segments • Customers • Geographies • Business Models SUSTAINABILITY • Economic • People • Societal • Environmental GROWTH Revenue Profitability Cash Flow Compete in winning segments and geographies Achieve leading positions Deliver superior operating performance CORPORATE STRATEGY © 2026 Haemonetics Corporation4
Page 5
5 5 1) Based on the mid-point of the Company’s FY’26 guidance issued on November 6, 2025. 2) Free cash flow to adjusted net income c onversion ratio for the twelve trailing months as of Q2 FY’26. 3) Capital capacity is calculated as total cash plus available borrowings under the Company’s revolving credit facility up to a maximum consolidated net leverage ratio of 4.5X EBITDA. 4)Recurring revenue includes single-use disposables and software. Attractive business model & leading share across three main growth products of revenue is recurring4 FY’22-FY’26E1 ~8% Revenue CAGR ~17% Adjusted EPS CAGR +~770bps In adjusted operating margins ~13% Organic revenue CAGR ex. CSL 94% Quality earnings and strong balance sheet 92% FCF conversion ratio2 Up to $1B in capital capacity available for value creation3 © 2026 Haemonetics Corporation A Durable, High-Return Model Built to Compound Value
Page 6
6 Portfolio Transformation Laying the Foundation for Sustainable Growth © 2026 Haemonetics Corporation High growth portfolio: mid single-digit to double-digit growth • Plasma • Blood Management Technologies • Interventional Technologies Legacy portfolio: low single-digit decline to flat • Blood Center (ongoing rationalization) +~8% 53% 47% 58% 42% 61% 39% 35% 65% 67% 33% 64% 36% 31% 69% 75% 25% 78% 22% 81% 19% ~84% ~16% 6 69% 31% 75% 25% 22% 78% 81% 84% 19% 16% FY22 FY23 FY24 FY25 FY'26E Revenue High Growth portfolio Durable Portfolio Includes ~$153M in portfolio transitions1 $993M $1,168M $1,309M $1,361M ~$1,300M2 1) Portfolio transitions include the impact of approximately $100M in fiscal 2025 U.S. disposables sales to CSL Plasma, $49M relating to the divestiture of the Whole Blood product line in January 2025, and the exit of certain liquids solution products. 2) Based on the mid-point of the Company’s FY’26 guidance issued on November 6, 2025. (Revenue growth%) 69% 31% 25% 75% 78% 22% 19% 81% 84% 16%
Page 7
7 Three Core Products With Leading Positions Driving Nearly All Revenue Growth Plasma Blood Management Technologies Interventional Technologies $535M $309M Hemostasis Management Transfusion Management Cell Salvage in plasma collections with NexSys PCS® $255M Vascular Closure Sensor Guided Technologies Esophageal Cooling #1 in viscoelastic testing with TEG®6s (Hemostasis Management) #1 in electrophysiology with VASCADE MVP® (Vascular Closure) #1 FY’25 Revenue FY’25 Revenue FY’25 Revenue 7 57% 57% 76% © 2026 Haemonetics Corporation
Page 8
8 Driving Sustained Market Leadership with Industry-Defining Plasma Innovation PLASMA SAM GROWTH DRIVERS: Demand for Immunoglobulins (Ig): • PID, SID, Others2 ~87% United States ~7% ROW ~$1B SAM1 DRIVERS OF REVENUE GROWTH Growth in plasma collections Innovation focused on top customer KPI’s Global market share expansion PLASMA MARKET ~50% Global HAE share3 The only provider of fully integrated plasma collection solutions focused on reducing Cost Per Liter (CPL) DELIVERING UNRIVALED PLASMA CENTER CAPABILITIES Yield1 Productivity2 Safety3 Donor Experience4 NexSys PCS® with Persona® Donor 360® NexLynk DMS® Device360® 1) Serviceable Addressable Market (SAM) is calculated as total plasma collections (excluding China) in fiscal year 2025 multiplied by the average selling price of Haemonetics’ total product offerings in each geography. [US plasma collections data is from PPTA, Europe & ROW collections data is from the “Global Blood & Plasma Collections and Use 2023/2024” report by MRB, Sep. 2025.] 2) Primary immunodeficiency (PID), Secondary immunodeficiency (SID), and Others include Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Immune Thrombocytopenic Purpura (ITP), and Myasthenia gravis (MG). 3) Global HAE share as of the fiscal year 2025 end. 8 growing MSD-HSD ~6% Europe Mature, growing market © 2026 Haemonetics Corporation
Page 9
Building Momentum and Making TEG® 6s the Standard for Viscoelastic Testing 1) Serviceable Addressable Market reflects existing commercial geographies and indications. Data sources include iData, DRG/Clarivate, MedTech Insight, and internal Company estimates. Includes the Top 7 geographies multiplied by average test utilization and average selling price in each geography. 2) Global HAE share of the total SAM in FY’25. 9 DRIVERS OF REVENUE GROWTH VISCOELASTIC TESTING (VET) MARKET ~$420M SAM1 ~20% Trauma ~77% CV Surgery ~3% Liver Transplant Real-time, actionable insight into coagulation status enabling clinicians to make rapid, targeted treatment decisions, improving patient outcomes while reducing costs and risks of unnecessary transfusions. Pipeline of innovation • Clinical segments • Product portfolio Legacy TEG® 5000 device upgrade cycle Penetration in the top 700 accounts in the US; international expansion VET SAM GROWTH DRIVERS: Growth in trauma and cardiac procedures ~45% HAE share2 TEG® 6s TEG Manager® software 9 ~78% United States ~14% Europe TEG® 6s is the only integrated VET system, and the only system offering PlateletMapping® functionality ~8% ROW growing MSD Developing market with a penetration rate of ~60% Global SAM © 2026 Haemonetics Corporation
Page 10
10 ~$600M SAM1 ELECTROPHYSIOLOGY MARKET 1) Serviceable Addressable Market reflects existing commercial geographies and is calculated as total procedure volumes multi plied by average selling price by region. Procedure data sourced from Clarivate and MRB. 2) Afib – Atrial Fibrillation ablation, LAAC - Left Atrial Appendage Closure, VT – Ventricular Tachycardia ablation, SVT – Supraventricular Tachycardia, FL – Atrial Flutter. 3) As demonstrated in the AMBULATE pivotal trial, compared to manual compression. 4) Patient satisfaction data on a scale of 0-10, with 0 being the worst and 10 being the best. 5) HAE share of the US SAM. ~65% Afib ~14% LAAC ~21% VT/SVT/FL Simple-to-use resorbable collagen plug that expands to fill the tissue track 64% reduction in median time to ambulation 63% Improvement in patient satisfaction4 58% Reduction in opioid Use Penetration into the Top 600 accounts in the US; international expansion Increase in the utilization of existing accounts EP MARKET GROWTH DRIVERS: Growth in LAAC and Afib procedures ~40% US HAE share5 US EP SAM2 VASCADE MVP® Robust clinical evidence3 supporting continued adoption and market share leadership in EP 10 Pipeline of innovation • Clinical segments • Product portfolio ~70% United States ~25% Europe ~5% Japan growing MSD - HSD Developing market with a penetration rate of ~60% (US) Expanding Market and Growth Momentum in Electrophysiology with Vascular Closure DRIVERS OF REVENUE GROWTH © 2026 Haemonetics Corporation
Page 11
11 Acquisition of Vivasure Unlocks Attractive TAM and Secures Category Leadership in Closure Category Leadership in Vascular Closure from 5F up to 22F in ID (up to 26F in OD) • Up to €185M in total purchase price • $300M attractive and growing TAM1 • Fully absorbable sutureless design with no need to pre-close. • 0% major complications through 30-day follow-up2 • Immediate median time to hemostasis3 ACQUISITION SUMMARY STRONG CLINICAL ADVANTAGES 1) Addressable procedures multiplied by ASP. 2) Results from the prospective, single-arm, multi-center ELITE study; N=106 arterial per-protocol subjects, access site device-related vascular complications per VARC-3 definition. 3) Results from the prospective, single-arm, multi-center ELITE study; N=109 arterial, per-protocol closures. 4) Vascade MVP® XL is pending FDA approval for label expansion up to 17F OD. 5) PerQseal Elite is available for sale in the EU; Not available for sale in the US, pending PMA approval for arterial indication. 11 Sheath Femoral Arterial and Venous Closure System Sheath Femoral Venous Closure System (up to 15F OD) Sheath Femoral Venous Closure System (up to 17F OD 4) VASCADE® VASCADE MVP® VASCADE MVP® XL PerQseal® Elite5 Sheath Femoral Arterial and Venous Closure System (up to 26F OD) 5F 7F 6F 12F 10F 14F 22F14F © 2026 Haemonetics Corporation 12F
Page 12
12 Adjusted Operating Margin % ~17% CAGR ~2.5X FY'22 FY'23 FY'24 FY'25 FY'26FY'22 FY'23 FY'24 FY'25 FY'26FY'22 FY'23 FY'24 FY'25 FY'26 18.8% 18.7% 21.1% 24.0% ~26.5% +~770bps $2.58 $3.03 $3.96 $4.57 ~$4.90 Adjusted EPS Free Cash Flow E1 12 1) The mid-point of the Company’s FY’26 guidance issued on November 6, 2025. A Track Record of Improving Profitability and Free Cash Flow $78M $164M $117M $145M ~$190M E1 E1 © 2026 Haemonetics Corporation
Page 13
Value-Enhancing Capital Allocation 13 A relentless focus on shareholder value creation ROIC increases from ~6.7% in FY’22 to ~11% in Q2 YTD FY’261 Consistent strong cash generation creates optionality for capital deployment 1) Please refer to Appendix E for the ROIC formula ~40% M&A ~28% Shareholder Returns ~32% Organic Investments $214 M $212 M $375 M $1.3B Deployed FY’22 – Q2 FY’26 Growth CAPEX R&DShare BuybacksM&A 13 © 2026 Haemonetics Corporation $515 M
Page 14
Appendices 14 © 2026 Haemonetics Corporation
Page 15
15 ($ millions) FY 20262 FY 2022 Mid-point of guidance Actual CAGR Revenue ~ $1,326.8 $993.2 7.5% Acquisitions and Divestitures1 ~($48.1) ($76.4) CSL US Disposables – ($102.4) Currency Impact ~($16.8) ($45.4) Organic Revenue, ex.CSL ~$1,261.9 $769.0 13.2% Appendix A: Reconciliation of GAAP Revenue to Organic Revenue, ex CSL Compounded Annual Growth Rate (CAGR) 1) Reflects revenue related to the Attune Medical, OpSens Inc. acquisitions and the divestiture of the Whole Blood business. 2) The mid-point of the Company’s FY’26 guidance issued on November 6, 2025. 15
Page 16
16 Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2025 Financial Results ($ millions) Gross profit Operating expenses Operating income (loss) Interest and other expense Provision (benefit) for income taxes Net income (loss) Earnings per diluted share Reported $749.0 $527.1 $221.8 ($9.7) $44.4 $167.7 $3.31 Amortization of acquired intangible assets – ($48.3) $48.3 – $12.0 $36.3 $0.72 Amortization of fair value inventory step up $15.0 – $15.0 – $3.6 $11.3 $0.22 Acquisition, integration and divestiture related costs $3.2 ($19.7) $22.9 ($2.5) $2.4 $18.0 $0.35 Restructuring costs $11.3 ($2.6) $13.9 – $3.5 $10.4 $0.21 Restructuring related costs $3.3 ($3.9) $7.2 – $1.7 $5.6 $0.11 Digital transformation costs – ($20.3) $20.3 – $4.8 $15.5 $0.30 Write downs of certain assets – ($4.0) $4.0 – $1.0 $3.0 $0.06 MDR and IVDR costs – ($4.8) $4.8 – $1.1 $3.7 $0.07 Litigation-related charges – ($2.9) $2.9 – $0.7 $2.2 $0.04 Gain on repurchase of convertible notes, net – – – ($12.6) ($3.1) ($9.5) ($0.19) Gain on sale of property, plant and equipment – $14.1 ($14.1) – ($3.4) ($10.7) ($0.21) Impairment of intangible assets – ($2.4) $2.4 – $0.6 $1.8 $0.04 Remeasurement of contingent consideration – $23.0 ($23.0) – ($0.1) ($23.0) ($0.45) Discrete tax items – – – – $0.7 ($0.7) ($0.01) Adjusted $781.8 $455.5 $326.3 ($24.8) $70.0 $231.5 $4.57 Adjusted, as a percentage of net revenues 57.4% 33.5% 24.0% 17.0% © 2026 Haemonetics Corporation16
Page 17
17 ($ millions) Gross profit Operating expenses Operating income (loss) Interest and other expense Provision (benefit) for income taxes Net income (loss) Earnings per diluted share Reported $691.5 $526.7 $164.9 ($13.0) $34.3 $117.6 $2.29 Amortization of acquired intangible assets – ($32.0) $32.0 – $8.2 $23.8 $0.46 Amortization of fair value inventory step up $3.3 – $3.3 – $0.9 $2.5 $0.05 Acquisition, integration and divestiture related costs – ($11.2) $11.2 – $1.3 $9.9 $0.19 Restructuring costs $11.3 ($2.8) $14.1 – $3.2 $10.9 $0.21 Restructuring related costs $5.7 ($3.8) $9.5 – $2.4 $7.1 $0.14 Digital transformation costs – ($15.7) $15.7 – $3.9 $11.8 $0.23 PCS2 related charges $0.3 ($4.8) $5.1 – $1.3 $3.8 $0.07 MDR and IVDR costs – ($5.6) $5.6 – $1.3 $4.3 $0.08 Litigation-related charges – ($6.7) $6.7 – $1.7 $5.0 $0.10 Impairment of intangible assets – ($10.4) $10.4 – $3.4 $7.0 $0.14 Gain on divestiture – $2.0 ($2.0) – ($0.5) ($1.5) ($0.03) Discrete tax items – – – – ($1.5) $1.5 $0.03 Adjusted $712.3 $435.7 $276.5 ($13.0) $59.9 $203.6 $3.96 Adjusted, as a percentage of net revenues 54.4% 33.3% 21.1% 15.6% Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2024 Financial Results © 2026 Haemonetics Corporation17
Page 18
18 ($ millions) Gross profit Operating expenses Operating income (loss) Interest and other expense Provision (benefit) for income taxes Net income (loss) Earnings per diluted share Reported $615.1 $459.1 $156.0 ($14.6) $26.0 $115.4 $2.24 Amortization of acquired intangible assets – ($32.6) $32.6 – $10.0 $22.7 $0.44 Integration and transaction costs – $0.4 ($0.4) – ($0.1) ($0.3) ($0.01) Restructuring costs ($0.2) ($0.9) $0.7 – $0.2 $0.5 $0.01 Restructuring related costs $8.0 ($2.9) $10.9 – $3.1 $7.8 $0.16 Digital transformation costs – ($4.5) $4.5 – $1.6 $3.0 $0.06 Write downs of certain in-process intangible assets and PCS2 related charges ($1.0) ($0.4) ($0.6) – ($0.2) ($0.4) ($0.01) MDR and IVDR costs $0.1 ($9.8) $9.9 – $2.8 $7.1 $0.14 Litigation-related charges – ($5.2) $5.2 – $1.8 $3.5 $0.07 Gain on sale of assets – $0.4 ($0.4) – ($0.1) ($0.3) ($0.01) Discrete tax adjustments – – – – $3.2 ($3.2) ($0.06) Adjusted $622.0 $403.6 $218.4 ($14.6) $48.1 $155.7 $3.03 Adjusted, as a percentage of net revenues 53.2% 34.5% 18.7% 13.3% Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2023 Financial Results © 2026 Haemonetics Corporation18
Page 19
19 ($ millions) Gross profit Operating expenses Operating income (loss) Interest and other expense Provision (benefit) for income taxes Net income (loss) Earnings per diluted share Reported $505.5 $424.8 $80.8 ($17.1) $20.3 $43.4 $0.84 Amortization of acquired intangible assets – ($47.4) $47.4 – $9.7 $37.7 $0.73 Integration and transaction costs $5.3 ($16.3) $21.6 – $4.5 $17.1 $0.33 Restructuring costs $2.2 ($2.0) $4.2 – $0.5 $3.7 $0.07 Restructuring related costs $17.8 ($6.8) $24.6 – $5.2 $19.4 $0.38 Impairment of assets and PCS2 related charges $4.9 ($0.9) $5.7 – $1.2 $4.5 $0.09 MDR and IVDR costs – ($11.0) $11.0 – $2.3 $8.7 $0.17 Litigation-related charges – ($1.4) $1.4 – $0.3 $1.1 $0.02 Gain on divestiture – $9.6 ($9.6) – ($2.0) ($7.6) ($0.15) Discrete tax adjustments – – – – ($4.6) $4.6 $0.10 Adjusted $535.7 $348.6 $187.1 ($17.1) $37.4 $132.6 $2.58 Adjusted, as a percentage of net revenues 53.9% 35.1% 18.8% 13.3% Appendix B: Reconciliation of GAAP to Non-GAAP Fiscal 2022 Financial Results © 2026 Haemonetics Corporation19
Page 20
20 ($ millions) FY 2025 FY 2024 FY 2023 FY 2022 Free Cash Flow Reconciliation Cash provided by operating activities $181.7 $181.7 $273.1 $172.3 Capital expenditures ($39.3) ($38.1) ($29.1) ($44.7) Additions to Haemonetics’ equipment ($21.1) ($28.2) ($81.1) ($51.8) Proceeds from sale of property, plant and equipment $23.3 $1.8 $1.6 $2.0 Free cash flow $144.6 $117.3 $164.5 $77.8 Appendix C: Reconciliation of Cash Flows © 2026 Haemonetics Corporation20
Page 21
21 GAAP Revenue and Organic Revenue Growth Guidance Plasma Blood Center Hospital Total Company Reported (4–7%) (17–19%) 4–7% (1–4%) Currency Impact – 1% – 1% Acquisitions & Divestitures1 – (19%) – (4%) Organic (4–7%) (1)–1% 4–7% (1)–2% CSL 2025 US disposables revenue2 21% – – 8% Organic, ex-CSL 14–17% (1)–1% 4–7% 7–10% Appendix D: Fiscal 2026 Guidance 1) Reflects adjustment in Blood Center to exclude the impact of the Company’s divestiture of its Whole Blood product line in January 2025 and exit of certain liquid solution products. 2) Reflects adjustment to exclude the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. Adjusted Operating Margin, Earnings per Share and Free Cash Flow Guidance Total Company Adjusted operating margin 26–27% Adjusted earnings per diluted share $4.80–$5.00 Free cash flow $170M–$210M Free cash flow to adjusted net income >70% © 2026 Haemonetics Corporation21
Page 22
22 22 © 2026 Haemonetics Corporation Appendix E: ROIC formula